Localized viral vector delivery to enhance in situ regenerative gene therapy

Engineering biomaterial systems to enhance viral vector gene delivery.

Integrating viral gene delivery with engineered biomaterials is a promising strategy to overcome a number of challenges associated with virus-mediated gene delivery, including inefficient delivery to specific cell types, limited tropism, spread of vectors to distant sites, and immune responses. Viral vectors can be combined with biomaterials either through encapsulation within the material or i...

Non-Viral Delivery Systems in Gene Therapy

Recent advances in molecular biology combined with the culmination of the Human Ge‐ nome Project [1] have provided a genetic understanding of cellular processes and disease pathogenesis; numerous genes involved in disease and cellular processes have been identi‐ fied as targets for therapeutic approaches. In addition, the development of high-throughput screening techniques (e.g., cDNA microarra...

Novel Viral Vector Systems for Gene Therapy

Targeted, non-viral gene delivery for cancer gene therapy.

The ability to mediate targeted and specific delivery of therapeutics to cancer cells remains one of the most important hurdles in effectively treating cancer. This aspect also remains as one of the greatest limitations of gene therapy as well. Targeted vectors based on the use of DNA-binding agents attached to cell specific ligands or "molecular conjugates" were created with the goal of over-c...

Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

Numerous biologic approaches are being investigated as anti-cancer therapies in an attempt to induce tumor regression while circumventing the toxic side effects associated with standard chemo- or radiotherapies. Among these, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown particular promise in pre-clinical and early clinical trials, due to its preferential ability to i...